These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9559312)

  • 1. Ranolazine: a novel metabolic modulator for the treatment of angina.
    McCormack JG; Stanley WC; Wolff AA
    Gen Pharmacol; 1998 May; 30(5):639-45. PubMed ID: 9559312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
    Bhandari B; Subramanian L
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):35-9. PubMed ID: 18221101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranolazine: a potential new treatment for chronic stable angina.
    Anderson JR; Khou S; Nawarskas JJ
    Heart Dis; 2001; 3(4):263-9. PubMed ID: 11975803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranolazine. A metabolic modulator for the treatment of chronic stable angina.
    Anderson JR; Nawarskas JJ
    Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
    Rupp H; Zarain-Herzberg A; Maisch B
    Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial fatty acid oxidation inhibitors for stable angina.
    Stanley WC
    Expert Opin Investig Drugs; 2002 May; 11(5):615-29. PubMed ID: 11996644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranolazine CV Therapeutics.
    Marzilli M
    Curr Opin Investig Drugs; 2005 Mar; 6(3):336-43. PubMed ID: 15816511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
    Chaitman BR
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
    Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
    J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecule of the month: ranolazine.
    Drug News Perspect; 2003; 16(6):391. PubMed ID: 12973449
    [No Abstract]   [Full Text] [Related]  

  • 11. Ranolazine in patients with angina and coronary artery disease.
    Scirica BM; Morrow DA
    Curr Cardiol Rep; 2007 Jul; 9(4):272-8. PubMed ID: 17601393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranolazine, a novel agent for chronic stable angina.
    Gaffney SM
    Pharmacotherapy; 2006 Jan; 26(1):135-42. PubMed ID: 16506355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angina drug shifts heart muscle's fuel use. Compelling the heart to burn more blood sugar and less fat appears to boost cardiac efficiency.
    Heart Advis; 2002 Apr; 5(4):2. PubMed ID: 16294391
    [No Abstract]   [Full Text] [Related]  

  • 14. Ranolazine: focusing on angina pectoris.
    McCullough PA
    Drugs Today (Barc); 2006 Mar; 42(3):177-83. PubMed ID: 16628259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial fatty acid oxidation (pFOX) inhibition: a new therapy for chronic stable angina.
    Conti CR
    Clin Cardiol; 2003 Apr; 26(4):161-2. PubMed ID: 12708620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
    Rousseau MF; Pouleur H; Cocco G; Wolff AA
    Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease.
    Bagger JP; Bøtker HE; Thomassen A; Nielsen TT
    Cardiovasc Drugs Ther; 1997 Jul; 11(3):479-84. PubMed ID: 9310277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranolazine: new approach for the treatment of stable angina pectoris.
    Stanley WC
    Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):821-9. PubMed ID: 16181027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ranolazine--an additional anti-anginal drug].
    Michels G; Kochanek M; Hoppe UC
    Dtsch Med Wochenschr; 2010 Oct; 135(41):2037-40. PubMed ID: 20925013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.